About US World Meds
US World Meds is a Healthcare company based in Louisville (United States) founded in 2001. Therapeutics for multiple diseases are developed by US World Meds. US World Meds has raised $148.52 million across 4 funding rounds from investors including Highland Capital Partners and Thomas, McNerney & Partners. The company has 216 employees. US World Meds offers products and services including Pharmaceutical Products. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is US WORLDMEDS LLC. Its competitors include Biogen, Denali Therapeutics and Intra-Cellular Therapies; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2001 and based in Louisville, United States, therapeutics for various diseases are developed by US World Meds in the pharmaceutical sector. Operations focus on drugs such as APOKYN for Parkinsons disease, CORGARD for hypertension and angina, MYOBLOC for cervical dystonia, REVONTO for malignant hyperthermia, and XADAGO for Parkinsons treatment. Distribution occurs through established medical channels.
- Headquarters Louisville, United States
- Employees 216
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website usworldmeds.com
- Social LinkedIn X Facebook
- Legal Name Us Worldmeds Llc
- Total Equity Funding$148.52M (USD)
in 4 rounds
- Latest Funding Round$55.52M (USD), Series B
May 2007
- InvestorsHighland Capital Partners
& 1 more
- Employee Count216
Products & Services of US World Meds
US World Meds offers a comprehensive portfolio of products and services, including Pharmaceutical Products.
Products designed to improve lives of patients with unmet medical needs
Funding Insights of US World Meds
US World Meds has successfully raised a total of $148.52M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $55.52 million completed in May 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $148.52M
- Total Rounds 4
- Last Round Series B — $55.52M
- First Round $8M
(Jul 2005)
- Investors Count 2
All 4 funding rounds of US World Meds with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2007 | $55.52M | Series B | – | – | – |
| Nov 2006 | Debt – Conventional | – | – | ||
| Nov 2006 | $85M | Series B | – | – | |
| Jul 2005 | $8M | Series A | – | – | – |
2 investors in total: 2 institutional.
Investors in US World Meds
US World Meds has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Highland Capital Partners and Thomas, McNerney & Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investment and entrepreneur support services. | hcp.com | |||
| tm-partners.com |
Investor details for US World Meds
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of US World Meds
39 people are tracked at US World Meds (21 in leadership, 18 in team); the tracked headcount is 216.
| Name | Role | Group |
|---|---|---|
Thomas Clinch | Vice President Research And Development | Leadership |
Fran Brophy | Senior Director, Clinical Programs, Clinical Product Lead | Leadership |
H. Lee Warren, Jr | Chief Operating Officer | Leadership |
Paul Breckinridge Jones | CEO | Leadership |
Robert Gilkin | VP, Commerical Operations & Market Access | Leadership |
Elizabeth Mirarchi | Director, Supply Chain | Leadership |
Tracy Elko | Director, Project Management | Leadership |
Tianjiao Wang | Director, Clinical Biomarkers & Companion Diagnostics | Leadership |
Breck Jones, Jr | Managing Director, Recovery Business | Leadership |
George Digenis | Chief Scientific Officer | Leadership |
Henry van den Berg | Senior Vice President | Leadership |
Kristen Gullo | VP, Development & Regulatory Affairs | Leadership |
Stephanie Montgomery | VP, Finance | Leadership |
Randal Seburg | Director, CMC Product Development | Leadership |
Dan Hodge | Senior Director Manufacturing Operations | Leadership |
Crystal Grinter | Director Of IT | Leadership |
Cheryl Custard | Director, GMP Training & Quality Systems | Leadership |
Greg Godi | National Sales Director, Oncology Division | Leadership |
Daniel Gilbert | Director, Manufacturing & MES | Leadership |
Michael Nathenson | Senior Medical Director | Leadership |
19 more people are available in the full profile.
Complete people profiles for US World Meds
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of US World Meds
3 dated milestones of US World Meds across 6 years, from founding to its latest funding, stage changes and deals.
- Founded US World Meds is founded.
- Funding First funding round of $8.0M.
- Funding Latest funding round, Series B, of $55.5M.
Competitors of US World Meds
US World Meds has 3 listed competitors in our database, 3 of them funded. They include Biogen, Denali Therapeutics and Intra-Cellular Therapies.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| intracellulartherapies.com | 2002 | New York, United States | $80.87M | 600 | Developer of therapeutics for psychiatric and neurologic diseases |
Detailed competitors of US World Meds
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of US World Meds
The website of US World Meds (usworldmeds.com) receives about 2.6K visits a month and ranks #9,223,689 among all websites worldwide, #7,618 in Biotechnology and Pharmaceuticals.
- Monthly visits2.6K
▲ 55.7% vs previous month
- Global rank#9,223,689
among all websites
- Category rank#7,618
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.7
- Average visit28 sec
- DevicesDesktop 44% · Mobile 56%
Websites whose visitors overlap most with US World Meds. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
stalevo.com | stalevo.com | 100% | – | ||
| lctglobal.com | 100% | View details | |||
ucb-usa.com | ucb-usa.com | 100% | #1,210,289 | – | |
| drugfree.org | 78% | 111.3K | #363,627 | View details | |
azilect.com | azilect.com | 62% | #11,510,251 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for US World Meds
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as US World Meds (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Us World Meds
Complete news archive for US World Meds
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about US World Meds
US World Meds was founded in 2001 and raised its 1st funding round 4 years after it was founded.
US World Meds is headquartered in Louisville, United States. It is registered at Louisville, Kentucky, United States.
US World Meds is a funded company, having raised a total of $148.52M across 4 funding rounds to date. The company's 1st funding round was a Series A of $8M, raised on Jul 2005.
US World Meds has 216 employees.
Founded in 2001 and based in Louisville, United States, therapeutics for various diseases are developed by US World Meds in the pharmaceutical sector. Operations focus on drugs such as APOKYN for Parkinsons disease, CORGARD for hypertension and angina, MYOBLOC for cervical dystonia, REVONTO for malignant hyperthermia, and XADAGO for Parkinsons treatment. Distribution occurs through established medical channels.
US World Meds's top competitors include Intra-Cellular Therapies, Denali Therapeutics and Biogen.
US World Meds offers Pharmaceutical Products.
US World Meds has 2 investors. Key investors include Highland Capital Partners, and Thomas, McNerney & Partners.
US World Meds operates through Us Worldmeds Llc.